Prevalence of COVID-19 among patients with rheumatic diseases: The need to await results from large collaborative studies. Response to: 'COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs' by Conticini et al

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Article number202021773
JournalAnnals of the Rheumatic Diseases
Publication statusAccepted/In press - Jan 1 2020


  • antirheumatic agents
  • arthritis
  • biological therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this